How many Italian cancer patients are eligible for, and may respond to, Italian Medicines Agency-approved immune checkpoint inhibitors?

IF 2 4区医学 Q3 ONCOLOGY

Tumori Pub Date : 2024-04-01 Epub Date: 2024-02-19 DOI:10.1177/03008916241229649

Emanuele Crocetti, Alessandra Ravaioli, Fabio Falcini, Rosa Vattiato, Silvia Mancini, Flavia Baldacchini, Federica Zamagni, Benedetta Vitali, Chiara Balducci, Lauro Bucchi, Orietta Giuliani

{"title":"How many Italian cancer patients are eligible for, and may respond to, Italian Medicines Agency-approved immune checkpoint inhibitors?","authors":"Emanuele Crocetti, Alessandra Ravaioli, Fabio Falcini, Rosa Vattiato, Silvia Mancini, Flavia Baldacchini, Federica Zamagni, Benedetta Vitali, Chiara Balducci, Lauro Bucchi, Orietta Giuliani","doi":"10.1177/03008916241229649","DOIUrl":null,"url":null,"abstract":"Introduction: This cross-sectional study was aimed at estimating the number of Italian incident cancer patients in 2020 eligible for, and respondent to, immune checkpoint inhibitors (ICI).Methods: The study is based on publicly available data: the ICI approved until August 2022 by the Italian Medicines Agency (AIFA) with their specific indications and overall observed responses, rther details can be found in the Online Supplementary Materi cancer incidence estimates at 2020 and observed cancer deaths, and published papers with estimates on the frequency of different cancer stage/histology/markers etc. corresponding to AIFA authorizations.Results: In the analyzed period, a total of seven ICI were authorized in Italy for 20 cancer types. The estimated number of ICI-eligible patients in 2020 was 48,400, 14.3% of those tumors (including skin epitheliomas) that may fit AIFA-indications, and 10.5% of all the incident malignant tumors, including skin epitheliomas. The number of patients who may benefit from ICI therapy was 24,052, 49.7% of the ICI-eligible ones, or 5.2% of the overall estimated incident cancers in 2020.Conclusions: In conclusion, although the number of ICI-eligible patients is a relatively small proportion of the yearly burden of cancers, about half of them may respond to ICI-treatment.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"109-115"},"PeriodicalIF":2.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11005312/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03008916241229649","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: This cross-sectional study was aimed at estimating the number of Italian incident cancer patients in 2020 eligible for, and respondent to, immune checkpoint inhibitors (ICI).

Methods: The study is based on publicly available data: the ICI approved until August 2022 by the Italian Medicines Agency (AIFA) with their specific indications and overall observed responses, rther details can be found in the Online Supplementary Materi cancer incidence estimates at 2020 and observed cancer deaths, and published papers with estimates on the frequency of different cancer stage/histology/markers etc. corresponding to AIFA authorizations.

Results: In the analyzed period, a total of seven ICI were authorized in Italy for 20 cancer types. The estimated number of ICI-eligible patients in 2020 was 48,400, 14.3% of those tumors (including skin epitheliomas) that may fit AIFA-indications, and 10.5% of all the incident malignant tumors, including skin epitheliomas. The number of patients who may benefit from ICI therapy was 24,052, 49.7% of the ICI-eligible ones, or 5.2% of the overall estimated incident cancers in 2020.

Conclusions: In conclusion, although the number of ICI-eligible patients is a relatively small proportion of the yearly burden of cancers, about half of them may respond to ICI-treatment.

查看原文本刊更多论文

有多少意大利癌症患者有资格使用意大利药品管理局批准的检查点免疫抑制药，并可能对其产生反应？

导言：这项横断面研究旨在估算 2020 年有资格使用免疫检查点抑制剂（ICI）的意大利癌症患者人数：这项横断面研究旨在估算 2020 年符合免疫检查点抑制剂（ICI）治疗条件和应答的意大利癌症患者人数：研究基于公开数据：意大利药品管理局（AIFA）批准的2022年8月前的ICI及其具体适应症和总体观察反应，更多详情可参见在线补充材料：2020年癌症发病率估计值和观察到的癌症死亡人数，以及与AIFA授权相对应的不同癌症分期/组织学/标志物等频率估计值的已发表论文：在分析期内，意大利共批准了 7 种 ICI，用于治疗 20 种癌症。据估计，2020 年符合 ICI 治疗条件的患者人数为 48,400 人，占可能符合 AIFA 适应症的肿瘤（包括皮肤上皮瘤）的 14.3%，占所有恶性肿瘤（包括皮肤上皮瘤）的 10.5%。可能从 ICI 治疗中获益的患者人数为 24,052 人，占符合 ICI 治疗条件的患者人数的 49.7%，或占 2020 年预计发生的癌症总数的 5.2%：总之，虽然符合 ICI 治疗条件的患者人数在每年的癌症发病率中所占比例较小，但其中约有一半的患者可能会对 ICI 治疗产生反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumori 医学-肿瘤学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Tumori Journal covers all aspects of cancer science and clinical practice with a strong focus on prevention, translational medicine and clinically relevant reports. We invite the publication of randomized trials and reports on large, consecutive patient series that investigate the real impact of new techniques, drugs and devices inday-to-day clinical practice.